Equities

Cronos Group Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Cronos Group Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.57
  • Today's Change0.00 / 0.00%
  • Shares traded1.56m
  • 1 Year change+27.86%
  • Beta1.2372
Data delayed at least 15 minutes, as of Mar 06 2026 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Cronos Group Inc had net income fall from a gain of 41.08m to a loss of 9.45m despite a 24.63% increase in revenues from 117.62m to 146.59m.
Gross margin42.81%
Net profit margin-2.00%
Operating margin-11.87%
Return on assets-0.25%
Return on equity-0.88%
Return on investment-0.27%
More ▼

Cash flow in USDView more

In 2025, cash reserves at Cronos Group Inc fell by 67.01m. However, the company earned 25.87m from its operations for a Cash Flow Margin of 17.65%. In addition the company used 76.56m on investing activities and also paid 19.91m in financing cash flows.
Cash flow per share0.0305
Price/Cash flow per share112.69
Book value per share3.89
Tangible book value per share3.62
More ▼

Balance sheet in USDView more

Cronos Group Inc appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio19.59
Quick ratio18.62
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.